These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1117 related articles for article (PubMed ID: 8949573)

  • 1. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
    Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
    Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
    Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Iranmanesh A; Veldhuis JD; Bouillon R
    Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
    Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone.
    De Marinis L; Mancini A; Valle D; Bianchi A; Gentilella R; Liberale I; Mignani V; Pennisi M; Della Corte F
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):741-7. PubMed ID: 10468946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations.
    Van den Berghe G; de Zegher F; Vlasselaers D; Schetz M; Verwaest C; Ferdinande P; Lauwers P
    Crit Care Med; 1996 Apr; 24(4):590-5. PubMed ID: 8612408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
    Van den Berghe G; Wouters P; Weekers F; Mohan S; Baxter RC; Veldhuis JD; Bowers CY; Bouillon R
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly.
    Hanew K; Utsumi A; Sugawara A; Shimizu Y; Abe K
    J Clin Endocrinol Metab; 1994 Mar; 78(3):509-12. PubMed ID: 8126120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.
    Pimentel-Filho FR; Ramos-Dias JC; Ninno FB; Façanha CF; Liberman B; Lengyel AM
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):295-300. PubMed ID: 9156038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
    Alba-Roth J; Müller OA; Schopohl J; von Werder K
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.